Aptinyx (NASDAQ:APTX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company’s product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in clinical stage. Aptinyx Inc. is based in IL, United States. “

A number of other research firms also recently weighed in on APTX. Cantor Fitzgerald restated a “buy” rating and issued a $40.00 target price on shares of Aptinyx in a research report on Monday, December 3rd. Leerink Swann dropped their target price on Aptinyx from $35.00 to $22.00 and set an “outperform” rating for the company in a research report on Thursday, January 17th. JPMorgan Chase & Co. downgraded Aptinyx from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $30.00 to $8.00 in a research report on Thursday, January 17th. Finally, BMO Capital Markets dropped their target price on Aptinyx to $18.00 and set an “outperform” rating for the company in a research report on Friday, January 18th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Aptinyx has a consensus rating of “Buy” and a consensus price target of $18.80.

NASDAQ:APTX opened at $4.01 on Tuesday. Aptinyx has a 1-year low of $3.90 and a 1-year high of $32.25.

In other news, CFO Ashish Khanna bought 10,000 shares of the company’s stock in a transaction that occurred on Friday, January 18th. The stock was bought at an average price of $5.45 per share, for a total transaction of $54,500.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Robert J. Hombach bought 25,000 shares of the company’s stock in a transaction that occurred on Friday, January 25th. The stock was purchased at an average price of $5.53 per share, with a total value of $138,250.00. The disclosure for this purchase can be found here. Insiders purchased a total of 36,050 shares of company stock valued at $198,284 in the last 90 days.

Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in Aptinyx by 1,822.7% in the third quarter. BlackRock Inc. now owns 769,072 shares of the company’s stock valued at $22,272,000 after purchasing an additional 729,072 shares during the last quarter. Partner Fund Management L.P. lifted its position in Aptinyx by 27.2% in the third quarter. Partner Fund Management L.P. now owns 1,754,679 shares of the company’s stock valued at $49,520,000 after purchasing an additional 374,763 shares during the last quarter. Vanguard Group Inc lifted its position in Aptinyx by 371.0% in the third quarter. Vanguard Group Inc now owns 296,717 shares of the company’s stock valued at $8,593,000 after purchasing an additional 233,717 shares during the last quarter. Vanguard Group Inc. lifted its position in Aptinyx by 371.0% in the third quarter. Vanguard Group Inc. now owns 296,717 shares of the company’s stock valued at $8,593,000 after purchasing an additional 233,717 shares during the last quarter. Finally, Citadel Advisors LLC lifted its position in Aptinyx by 231.1% in the third quarter. Citadel Advisors LLC now owns 314,005 shares of the company’s stock valued at $9,093,000 after purchasing an additional 219,168 shares during the last quarter. Institutional investors own 63.11% of the company’s stock.

Aptinyx Company Profile

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Recommended Story: What is the return on assets (ROA) ratio?

Get a free copy of the Zacks research report on Aptinyx (APTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.